Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Bleakley Financial Group LLC

Bleakley Financial Group LLC lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,139 shares of the medical equipment provider’s stock after selling 350 shares during the period. Bleakley Financial Group LLC’s holdings in Zimmer Biomet were worth $260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Olstein Capital Management L.P. raised its holdings in shares of Zimmer Biomet by 16.9% in the fourth quarter. Olstein Capital Management L.P. now owns 66,635 shares of the medical equipment provider’s stock valued at $8,109,000 after buying an additional 9,635 shares during the last quarter. Meeder Advisory Services Inc. purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $230,000. Stratos Wealth Partners LTD. raised its holdings in shares of Zimmer Biomet by 4.2% in the fourth quarter. Stratos Wealth Partners LTD. now owns 9,880 shares of the medical equipment provider’s stock valued at $1,202,000 after buying an additional 402 shares during the last quarter. Stratos Wealth Advisors LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $247,000. Finally, New York State Teachers Retirement System raised its holdings in shares of Zimmer Biomet by 2.6% in the fourth quarter. New York State Teachers Retirement System now owns 207,061 shares of the medical equipment provider’s stock valued at $25,199,000 after buying an additional 5,239 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares in the company, valued at $5,677,929.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on ZBH. Barclays upped their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, February 12th. StockNews.com cut shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. Canaccord Genuity Group reissued a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. Evercore ISI increased their price target on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Finally, Raymond James increased their price target on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $139.39.

Zimmer Biomet Trading Down 0.4 %

Shares of ZBH opened at $124.00 on Tuesday. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The firm’s 50-day moving average is $126.70 and its two-hundred day moving average is $119.02. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $149.25. The firm has a market capitalization of $25.48 billion, a P/E ratio of 25.36, a PEG ratio of 2.29 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.88 earnings per share. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.77%. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.